The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform

Masayoshi Inoue - One of the best experts on this subject based on the ideXlab platform.

  • High Neutrophil Count as a Negative Prognostic Factor for Relapse in Patients with Thymic Epithelial Tumor
    Annals of Surgical Oncology, 2020
    Co-Authors: Satoru Okada, Satoshi Teramukai, Masanori Shimomura, Hiroaki Tsunezuka, Shunta Ishihara, Satoshi Ikebe, Tatsuo Furuya, Junichi Shimada, Masayoshi Inoue
    Abstract:

    Purpose Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment Peripheral Blood Cell counts in patients with thymic epithelial tumors (TETs). Methods A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment Peripheral Blood Cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence. Results High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 10^3) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group ( p  = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence ( p  = 0.005 and p 

  • high neutrophil count as a negative prognostic factor for relapse in patients with thymic epithelial tumor
    Annals of Surgical Oncology, 2020
    Co-Authors: Satoru Okada, Satoshi Teramukai, Masanori Shimomura, Hiroaki Tsunezuka, Shunta Ishihara, Satoshi Ikebe, Tatsuo Furuya, Junichi Shimada, Masayoshi Inoue
    Abstract:

    Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment Peripheral Blood Cell counts in patients with thymic epithelial tumors (TETs). A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment Peripheral Blood Cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence. High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 103) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group (p = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence (p = 0.005 and p < 0.001, respectively). The risk scoring system comprising high Neut count, advanced stage, and aggressive histology demonstrated better prognostic ability than any prognostic factors alone. High Neut count significantly correlated with TET recurrence, suggesting a negative prognostic effect of latent inflammation in TET patients.

Satoru Okada - One of the best experts on this subject based on the ideXlab platform.

  • High Neutrophil Count as a Negative Prognostic Factor for Relapse in Patients with Thymic Epithelial Tumor
    Annals of Surgical Oncology, 2020
    Co-Authors: Satoru Okada, Satoshi Teramukai, Masanori Shimomura, Hiroaki Tsunezuka, Shunta Ishihara, Satoshi Ikebe, Tatsuo Furuya, Junichi Shimada, Masayoshi Inoue
    Abstract:

    Purpose Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment Peripheral Blood Cell counts in patients with thymic epithelial tumors (TETs). Methods A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment Peripheral Blood Cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence. Results High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 10^3) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group ( p  = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence ( p  = 0.005 and p 

  • high neutrophil count as a negative prognostic factor for relapse in patients with thymic epithelial tumor
    Annals of Surgical Oncology, 2020
    Co-Authors: Satoru Okada, Satoshi Teramukai, Masanori Shimomura, Hiroaki Tsunezuka, Shunta Ishihara, Satoshi Ikebe, Tatsuo Furuya, Junichi Shimada, Masayoshi Inoue
    Abstract:

    Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment Peripheral Blood Cell counts in patients with thymic epithelial tumors (TETs). A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment Peripheral Blood Cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence. High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 103) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group (p = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence (p = 0.005 and p < 0.001, respectively). The risk scoring system comprising high Neut count, advanced stage, and aggressive histology demonstrated better prognostic ability than any prognostic factors alone. High Neut count significantly correlated with TET recurrence, suggesting a negative prognostic effect of latent inflammation in TET patients.

Guang Ning - One of the best experts on this subject based on the ideXlab platform.

  • Acute Response of Peripheral Blood Cell to Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetic Patient
    2016
    Co-Authors: Xiaofang Zhang, Wei Tang, Ruixin Liu, Minglan Yang, Jie Hong, Guang Ning
    Abstract:

    Objective: Autologous nonmyeloablative hematopoietic stem Cell transplantation (AHST) was the first therapeutic approach that can improve b Cell function in type 1 diabetic (T1D) patients. This study was designed to investigate the potential mechanisms involved. Design and methods: We applied AHST to nine T1D patients diagnosed within six months and analyzed the acute responses in Peripheral Blood for lymphocyte subpopulation as well as for genomic expression profiling at the six-month follow-up. Results: We found six patients obtained insulin free (IF group) and three remained insulin dependent (ID group); C-peptide production was significantly higher in IF group compared to ID group. The acute responses in lymphocytes at six-month follow-up include declined CD3+CD4+, CD3+CD8+ T Cell population and recovered B Cell, NK Cell population in both groups but with no significant differences between the two groups; most immune-related genes and pathways were up-regulated in Peripheral Blood mononuclear Cell (PBMC) of both groups while none of transcription factors for immune regulatory component were significantly changed; the IF group demonstrated more AHST-modified genetic events than the ID group and distinct pattern of top pathways, co-expression network as well as ‘hub ’ genes (eg, TCF7 and GZMA) were associated with each group

  • acute response of Peripheral Blood Cell to autologous hematopoietic stem Cell transplantation in type 1 diabetic patient
    PLOS ONE, 2012
    Co-Authors: Xiaofang Zhang, Wei Tang, Ruixin Liu, Minglan Yang, Jie Hong, Weiqing Wang, Guang Ning
    Abstract:

    Objective Autologous nonmyeloablative hematopoietic stem Cell transplantation (AHST) was the first therapeutic approach that can improve β Cell function in type 1 diabetic (T1D) patients. This study was designed to investigate the potential mechanisms involved. Design and methods We applied AHST to nine T1D patients diagnosed within six months and analyzed the acute responses in Peripheral Blood for lymphocyte subpopulation as well as for genomic expression profiling at the six-month follow-up. Results We found six patients obtained insulin free (IF group) and three remained insulin dependent (ID group); C-peptide production was significantly higher in IF group compared to ID group. The acute responses in lymphocytes at six-month follow-up include declined CD3(+)CD4(+), CD3(+)CD8(+) T Cell population and recovered B Cell, NK Cell population in both groups but with no significant differences between the two groups; most immune-related genes and pathways were up-regulated in Peripheral Blood mononuclear Cell (PBMC) of both groups while none of transcription factors for immune regulatory component were significantly changed; the IF group demonstrated more AHST-modified genetic events than the ID group and distinct pattern of top pathways, co-expression network as well as 'hub' genes (eg, TCF7 and GZMA) were associated with each group. Conclusions AHST could improve the islet function in newly diagnosed T1D patients and elimination of the islet specific autoreactive T Cells might be one of the mechanisms involved; T1D patients responded differently to AHST possibly due to the distinct transcriptional events occurring in PBMC. Trial registration ClinicalTrials.gov NCT00807651.

Tatsuo Furuya - One of the best experts on this subject based on the ideXlab platform.

  • High Neutrophil Count as a Negative Prognostic Factor for Relapse in Patients with Thymic Epithelial Tumor
    Annals of Surgical Oncology, 2020
    Co-Authors: Satoru Okada, Satoshi Teramukai, Masanori Shimomura, Hiroaki Tsunezuka, Shunta Ishihara, Satoshi Ikebe, Tatsuo Furuya, Junichi Shimada, Masayoshi Inoue
    Abstract:

    Purpose Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment Peripheral Blood Cell counts in patients with thymic epithelial tumors (TETs). Methods A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment Peripheral Blood Cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence. Results High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 10^3) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group ( p  = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence ( p  = 0.005 and p 

  • high neutrophil count as a negative prognostic factor for relapse in patients with thymic epithelial tumor
    Annals of Surgical Oncology, 2020
    Co-Authors: Satoru Okada, Satoshi Teramukai, Masanori Shimomura, Hiroaki Tsunezuka, Shunta Ishihara, Satoshi Ikebe, Tatsuo Furuya, Junichi Shimada, Masayoshi Inoue
    Abstract:

    Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment Peripheral Blood Cell counts in patients with thymic epithelial tumors (TETs). A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment Peripheral Blood Cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence. High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 103) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group (p = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence (p = 0.005 and p < 0.001, respectively). The risk scoring system comprising high Neut count, advanced stage, and aggressive histology demonstrated better prognostic ability than any prognostic factors alone. High Neut count significantly correlated with TET recurrence, suggesting a negative prognostic effect of latent inflammation in TET patients.

Shunta Ishihara - One of the best experts on this subject based on the ideXlab platform.

  • High Neutrophil Count as a Negative Prognostic Factor for Relapse in Patients with Thymic Epithelial Tumor
    Annals of Surgical Oncology, 2020
    Co-Authors: Satoru Okada, Satoshi Teramukai, Masanori Shimomura, Hiroaki Tsunezuka, Shunta Ishihara, Satoshi Ikebe, Tatsuo Furuya, Junichi Shimada, Masayoshi Inoue
    Abstract:

    Purpose Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment Peripheral Blood Cell counts in patients with thymic epithelial tumors (TETs). Methods A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment Peripheral Blood Cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence. Results High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 10^3) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group ( p  = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence ( p  = 0.005 and p 

  • high neutrophil count as a negative prognostic factor for relapse in patients with thymic epithelial tumor
    Annals of Surgical Oncology, 2020
    Co-Authors: Satoru Okada, Satoshi Teramukai, Masanori Shimomura, Hiroaki Tsunezuka, Shunta Ishihara, Satoshi Ikebe, Tatsuo Furuya, Junichi Shimada, Masayoshi Inoue
    Abstract:

    Preoperative neutrophil count is reportedly associated with poor prognosis in cancer patients. This study aimed to investigate the clinical significance of pre-treatment Peripheral Blood Cell counts in patients with thymic epithelial tumors (TETs). A retrospective review of 71 patients with completely resected TETs [64 thymoma, 6 thymic carcinoma, and 1 thymic neuroendocrine tumor] between 2000 and 2018 was conducted. Associations between tumor recurrence and pre-treatment Peripheral Blood Cell counts of leukocytes (WBC), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and platelets (Plt) were analyzed. Optimal cut-off points were selected using receiver operating characteristic curve analysis to predict tumor recurrence. High WBC (≥ 7000), Neut (≥ 4450), and Plt (≥ 226 × 103) counts had significantly poor relapse-free survival (RFS), but high Lymph (≥ 1950) and Mono (≥ 400) did not. High Neut had the strongest correlation with recurrence (area under curve, 0.800); we focused on the analysis between high-Neut and low-Neut groups. High Neut count significantly correlated with smoking history, pre-treatment C-reactive protein level, and advanced stage; high Neut count and aggressive histology tended to show correlations. RFS was significantly poorer in the high-Neut group than in the low-Neut group (p = 0.003), with 5-year RFS rates of 63.8% and 96.8%, respectively. High Neut count was a significant adverse predictor for RFS and cumulative incidence of recurrence (p = 0.005 and p < 0.001, respectively). The risk scoring system comprising high Neut count, advanced stage, and aggressive histology demonstrated better prognostic ability than any prognostic factors alone. High Neut count significantly correlated with TET recurrence, suggesting a negative prognostic effect of latent inflammation in TET patients.